Verici Dx plc

("Verici Dx" or the "Company")

Tutivia™ abstracts for World Transplant Congress

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that a number of abstracts relating to Tutivia™ have been published ahead of presentation at the forthcoming World Transplant Congress in San Francisco in August 2025 (WTC 2025), a major international event for experts in the field of organ transplantation to share research, discuss advancements, and address challenges in transplantation.

The abstracts focus on the role of biomarker testing with Tutivia™ to support medical management in important areas of unmet need including patients with BK nephropathy and increasing BK viremia, obese patients including those who underwent robotic transplantation, patients with delayed graft function (DGF) and slow graft function, and patients with previous failed transplant or multi-organ transplant.

The abstracts are based on real-world evidence collected at multiple transplant centres currently utilising Tutivia™ to support clinical care for these complex and challenging patient populations.

The World Transplant Congress is organised jointly by the American Society of Transplant Surgeons (ASTS), the American Society of Transplantation (AST), and The Transplantation Society (TTS). https://wtc2025.org/

The abstracts are available here:

(P1.07.253) Utility of Rejection Biomarker Tutivia in Managing Kidney Transplant Recipients at Risk of BK Nephropathy: https://cattendee.abstractsonline.com/meeting/21176/Session/306

(P3.07.218) Tutivia Biomarker Testing Provides Accurate Results for Medical Management in Severely Obese Kidney Transplant Patients: https://cattendee.abstractsonline.com/meeting/21176/Session/309

(P3.07.196) Use of TUTIVIA in the Early Post-Transplant Period for Distinction of Rejection from Quiescence Among Kidney Transplant Recipients - A Single Center Experience https://cattendee.abstractsonline.com/meeting/21176/Session/309

(P3.07.215) The Role of Gene Expression Profile in Predicting Acute Rejection https://cattendee.abstractsonline.com/meeting/21176/Session/309

(P3.07.216) Comparison of Gene Expression Profiling with Histopathology and Molecular Pathology in Detection of Acute Rejection in Kidney Transplant Recipients https://cattendee.abstractsonline.com/meeting/21176/Session/309

About Tutivia™  

The Tutivia™ test is an advancement in biomarker testing utilising RNA expression in peripheral blood and a proprietary algorithm to report a patient's risk score for acute rejection post-transplant. The Tutivia™ test is commercially available and already used in 20 ordering centres. Medicare coverage has supported the strong acceleration in adoption and test ordering volumes.

Commenting, Sara Barrington, CEO of Verici Dx, said: "It is a great validation of our test for acute rejection post-transplantation to have clinicians at multiple transplant centres sharing how it has been used to address important areas of unmet need.. Gaining shared clinical experience at leading transplant centers is essential to increase the adoption of Tutivia™ and in turn ultimately scale up volumes."